Literature DB >> 30556787

Measurement of patient-reported outcomes. 2: Are current measures failing us?

Stephen P McKenna1,2, Alice Heaney1, Jeanette Wilburn1.   

Abstract

All instruments designed to measure latent (unobservable) variables, such as patient-reported outcomes (PROs), have three major requirements; a coherent construct theory, a specification equation, and the application of an appropriate response model. The theory guides the selection of content for the questionnaire and the specification equation links the construct theory to scores produced with the instrument. For the specification equation to perform this role, the patient-reported outcome measure (PROM) must employ a response model that generates values for its individual items. The most commonly applied response model in PROM development is the Rasch model. To date this level of measurement sophistication has not been achieved in PRO measurement. Consequently, it is not possible to establish a PROM's true construct validity. However, the development of the Lexile Framework for Reading has demonstrated that such objective measurement is possible for latent variables. This article argues that higher quality PROM development is needed if meaningful and valid PRO measurement is to be achieved. It describes the current state of PROM development, shows that published reviews of PROMs adopt inappropriate criteria for judging their quality, and illustrates how the use of traditional PROMs can lead to incorrect (and possibly dangerous) conclusions being drawn about the efficacy of interventions.

Entities:  

Keywords:  C00; Construct validity; I10; Rasch Measurement Theory; objective measurement; patient reported outcome; questionnaire; response model; unidimensionality

Mesh:

Year:  2019        PMID: 30556787     DOI: 10.1080/13696998.2018.1560304

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  13 in total

1.  Value Assessment, Real World Evidence and Fundamental Measurement: Version 3.0 of the Minnesota Formulary Submission Guidelines.

Authors:  Paul C Langley
Journal:  Innov Pharm       Date:  2020-11-12

2.  To Dream the Impossible Dream: The Commitment by the Institute for Clinical and Economic Review to Rewrite the Axioms of Fundamental Measurement for Hemophilia A and Bladder Cancer Value Claims.

Authors:  Paul C Langley
Journal:  Innov Pharm       Date:  2020-12-10

3.  Medicaid Formulary Decisions and the Institute for Clinical and Economic Review: Abandoning Pseudoscience in Imaginary Pharmaceutical Pricing Claims.

Authors:  Paul C Langley
Journal:  Innov Pharm       Date:  2021-02-16

4.  Development of an Item Bank to Measure Medication Adherence: Systematic Review.

Authors:  Yu Heng Kwan; Livia Jia Yi Oo; Dionne Hui Fang Loh; Truls Østbye; Lian Leng Low; Hayden Barry Bosworth; Julian Thumboo; Jie Kie Phang; Si Dun Weng; Dan V Blalock; Eng Hui Chew; Kai Zhen Yap; Corrinne Yong Koon Tan; Sungwon Yoon; Warren Fong
Journal:  J Med Internet Res       Date:  2020-10-08       Impact factor: 5.428

5.  More Unnecessary Imaginary Worlds - Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease.

Authors:  Paul C Langley
Journal:  Innov Pharm       Date:  2020-04-30

6.  Yet another Ersatz World: The ICER Final Evidence Report for Additive Cardiovascular Therapies.

Authors:  Paul C Langley
Journal:  Innov Pharm       Date:  2019-10-31

7.  Value Assessment in Cystic Fibrosis: ICER's Rejection of the Axioms of Fundamental Measurement.

Authors:  Paul C Langley
Journal:  Innov Pharm       Date:  2020-04-30

8.  The Impossible QALY and the Denial of Fundamental Measurement: Rejecting the University of Washington Value Assessment of Targeted Immune Modulators (TIMS) in Ulcerative Colitis for the Institute for Clinical and Economic Review (ICER).

Authors:  Paul C Langley
Journal:  Innov Pharm       Date:  2020-07-31

9.  Collection and use of EQ-5D for follow-up, decision-making, and quality improvement in health care - the case of the Swedish National Quality Registries.

Authors:  Olivia Ernstsson; Mathieu F Janssen; Emelie Heintz
Journal:  J Patient Rep Outcomes       Date:  2020-09-16

10.  Measurement, modeling and QALYs.

Authors:  Paul C Langley; Stephen P McKenna
Journal:  F1000Res       Date:  2020-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.